Based on our extensive chemical compound screening we have revealed five specific ligands/inhibitors that bind at the hydrophobic region of the protein. The interaction of these ligands to the alpha-synuclein will stop fibril making and hence mitigate this disease. The current study will help to pave the way for innovative and novel treatments in the field of neurobiology and neurodegenerative diseases.